June 23, 2018
PHILADELPHIA (Embargoed until 4 p.m. EDT, Saturday, June 23, 2018) – A novel positron emission tomography (PET) tracer has been developed that can accurately image cardiovascular infections, which are extremely dangerous and have a high fatality rate. The research was presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
“Early diagnosis is crucial for proper patient management, as early treatment can improve prognosis and patient outcome,” Mirwais Wardak, PhD, at Stanford University School of Medicine in Stanford, California, points out. “In the clinic right now, we really lack the tools to be able to specifically image bacterial infections. To address this problem, we developed a novel PET tracer called 6ʹʹ-[18F]Fluoromaltotriose, which is transported into bacterial cells by the maltodextrin transporter, a membrane transport system that is exclusive to bacteria and not present on mammalian cells. To our knowledge, this is the first time that a fluorine-18 based PET tracer specific to bacteria has been used to image bacterial infection of the heart.”
For this study, the diagnostic accuracy of 6ʹʹ-[18F]Fluoromaltotriose PET/CT imaging was conducted in a Staphylococcus aureus-induced endocarditis mouse model. Wardak explains, “Endocarditis is an infection of the endocardium, which is the inner lining of the heart chambers and heart valves. Staphylococci bacteria are the most common causing agents of endocarditis.”
6′′-[18F]Fluoromaltotriose was able to image valvular infection with high sensitivity and specificity. Results showed an approximate 2.5-fold higher mean tracer uptake in the aortic valves of the infected mice when compared to the control mice.
Wardak states, “The results of this research overcome several fundamental limitations of current methods and promise to significantly impact the clinical management of patients suffering from infectious diseases of bacterial origin.” He adds, “We believe that 6ʹʹ-[18F]Fluoromaltotriose PET/CT will play a vital role in the detection and monitoring of bacterial infection in patients (e.g., as a result of cardiovascular infection, infection after surgery, medical device related infections, fever of unknown origin, etc.). We also believe that PET imaging with 6ʹʹ-[18F]Fluoromaltotriose will be helpful in the assessment of antibiotic therapy.”
Plans are currently underway to have this PET radiotracer translated into the clinic.
Looking ahead, Wardak and his colleagues also envision that 6ʹʹ-[18F]Fluoromaltotriose will be useful in other clinical settings beyond infectious disease. He explains, “For example, this tracer could be used to image the homing of bacteria against tumors, and could, therefore, be used to monitor bacteria that have been trained to kill tumors (e.g., Clostridium novyi engineered against glioblastoma cells).”
Figure 1. 6′′-[18F]Fluoromaltotriose is a new PET imaging agent that is able to visualize valvular infection of bacterial origin with high sensitivity and specificity. PET/CT imaging of a Staphylococcus aureus-induced endocarditis mouse model with 6ʹʹ-[18F]Fluoromaltotriose showed that the heart had the highest PET signal above the diaphragm (as it was the source of infection), while the kidneys had the highest signal below the diaphragm. Within the heart, the PET signal from the infected aortic valve had the highest uptake and could be clearly seen; in some cases, the tricuspid valve was also infected (similar to what is seen for intravenous drug users). Credit: Sanjiv Sam Gambhir, MD, PhD, Stanford University School of Medicine, Stanford, CA.
Abstract 36: “Molecular Imaging of Cardiovascular Infections with 6ʹʹ-[18F]-Fluoromaltotriose PET/CT,” Mirwais Wardak, PhD, Gayatri Gowrishankar, PhD, Xin Zhao, MD PhD, Mohammad Namavari, PhD, Yonggang Liu, MD PhD, Evgenios Neofytou, MD, Tom Haywood, PhD, Joseph C. Wu, MD PhD, and Sanjiv S. Gambhir, MD PhD, Stanford University School of Medicine, Stanford, CA. SNMMI’s 65th Annual Meeting, June 23-26, Philadelphia.
This research was supported by a National Institutes of Health grant (#5T32EB009035-08), and funding from the Department of Radiology, Stanford University School of Medicine.
Please visit the SNMMI Media Center for more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or email@example.com. 2018 SNMMI Annual Meeting abstracts can be found online at http://jnm.snmjournals.org/content/59/supplement_1. Current and past issues of The Journal of Nuclear Medicine are online at http://jnm.snmjournals.org.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s more than 16,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.